HC Wainwright Issues Positive Outlook for NeuroPace Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – HC Wainwright raised their FY2025 earnings per share (EPS) estimates for NeuroPace in a note issued to investors on Tuesday, January 27th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.68) for the year, up from their prior forecast of ($0.76). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for NeuroPace’s Q4 2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.85) EPS.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research report on Monday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price objective on shares of NeuroPace in a report on Wednesday, November 5th. Leerink Partners restated an “outperform” rating and set a $19.00 price objective on shares of NeuroPace in a research report on Wednesday, November 5th. JPMorgan Chase & Co. lifted their target price on NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Finally, Wells Fargo & Company increased their price target on NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.67.

NeuroPace Trading Down 1.2%

Shares of NPCE opened at $15.13 on Thursday. The firm has a market cap of $503.98 million, a P/E ratio of -19.91 and a beta of 1.85. The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 3.94. NeuroPace has a 1 year low of $7.56 and a 1 year high of $18.98. The company has a 50 day simple moving average of $16.27 and a two-hundred day simple moving average of $12.29.

NeuroPace (NASDAQ:NPCE) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.09. The firm had revenue of $27.35 million during the quarter, compared to analysts’ expectations of $24.64 million. NeuroPace had a negative return on equity of 136.60% and a negative net margin of 25.28%.

Hedge Funds Weigh In On NeuroPace

Several large investors have recently modified their holdings of NPCE. Palumbo Wealth Management LLC raised its holdings in NeuroPace by 8.5% during the 4th quarter. Palumbo Wealth Management LLC now owns 214,175 shares of the company’s stock valued at $3,307,000 after buying an additional 16,699 shares during the period. SG Americas Securities LLC purchased a new stake in shares of NeuroPace in the fourth quarter valued at $118,000. Tudor Investment Corp ET AL lifted its holdings in shares of NeuroPace by 29.3% in the 3rd quarter. Tudor Investment Corp ET AL now owns 153,698 shares of the company’s stock worth $1,585,000 after acquiring an additional 34,807 shares during the last quarter. Armistice Capital LLC lifted its holdings in shares of NeuroPace by 12.6% in the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock worth $13,382,000 after acquiring an additional 145,665 shares during the last quarter. Finally, PharVision Advisers LLC purchased a new position in shares of NeuroPace during the 3rd quarter worth about $232,000. Institutional investors own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.